Dosing & Administration

AMVUTTRA® is HCP-administered 4 times a year, providing the opportunity for consistent touchpoints in your patients’ healthcare routine1

AMVUTTRA® (vutrisiran) product image
Watch the administration video

AMVUTTRA® is HCP-administered 4 times a year, providing the opportunity for consistent touchpoints in your patients’ healthcare routine1

  • The recommended dose of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months by a healthcare professional.1

    AMVUTTRA is provided as a fixed dose (25 mg/0.5 mL) prefilled syringe—no dose adjustments are recommended.1

    (See section 2.2 of full Prescribing Information for complete Administration Instructions.)

  • If a dose is missed, administer AMVUTTRA as soon as possible. Resume dosing every 3 months from the most recently administered dose.1

HCP administration helps ensure confidence that each dose is administered fully and properly, without the need for premedication or laboratory monitoring.1

Picture of dosing and administration brochure

Learn more about dosing and administration.

Download brochure

AMVUTTRA requires the fewest doses to treat the polyneuropathy of hATTR amyloidosis1-3

  • AMVUTTRA® (vutrisiran) is dosed via an HCP-administered prefilled syringe 4 times a year.
  • Eplontersen is dosed monthly with a self-administered auto injector.
  • Patisiran is dosed as an HCP-administered infusion every 3 weeks.
  • AMVUTTRA offers you and your patient the flexibility to decide the best place to receive treatment—whether in your office, at a local clinic (one of the >1000 in the Alnylam Treatment Center Directories), or in the patient's homea

aIf covered by patient's insurance.

More than 1,300 patients are receiving treatment with AMVUTTRA in the US, making it the #1-prescribed treatment for the polyneuropathy of hATTR amyloidosis in adults.4

Administering AMVUTTRA
Administration of AMVUTTRA® (vutrisiran) video
00:00

Watch this instructional video for healthcare professionals

Walk through the steps for AMVUTTRA administration.

Find a treatment center
Find a treatment center

Locate a treatment center closest to your patients.

View the directory
Stay informed
Stay informed

Receive helpful information for you and your patients.

Sign up
Up next Learn about resources and links

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge MA: Alnylam Pharmaceuticals, Inc.
  2. ONPATTRO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  3. WAINUA Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
  4. Data on file. Alnylam Pharmaceuticals, Inc.